scholarly journals Actuarial Modelling for Patients with Acute Lymphoblastic Leukaemia (ALL) based on CNS1 Status

2021 ◽  
Vol 53 (03) ◽  
pp. 23-32
Author(s):  
Parmeet Kumar Vinit ◽  
Keyword(s):  
Prognostic Factors ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Deterministic Model ◽  
First Year ◽  
Insurance Plan ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier

Introduction: Worldwide, Acute Lymphoblastic Leukaemia (ALL) is the most frequent cancer in children. One of the major clinical challenges is adequate diagnosis and treatment of Central Nervous System (CNS) involvement in this disease. CNS relapse has been a barrier to the successful treatment of ALL for many years. Recent studies have shown encouraging results in the survival of these patients for a long time. However, their long-term survival depends upon the cost of therapy toxicity and financial distress. The primitive aim of the paper is to propose a yearly insurance plan to assist these patients financially during the diagnosis period. Method: Based on the CNS status 110 patients are categorised to estimate their long-term survival. Survival times of CNS1 status and for all the patients cumulatively are estimated by Kaplan-Meier and Cox-PH model in presence of the prognostic factors. The survival estimates are used to estimate the premium cost. The premium cost is estimated using a deterministic model which is advantageous for the patient and serviceable for the insurance provider. Result: Both the methods Kaplan-Meier and Cox-PH gave higher survival estimates for ALL patients cumulatively as compared to CNS1. Survival estimate from Cox-PH is 0.998 and 0.997 of first year of follow-up for patients taken cumulatively and in CNS1 respectively. For the fifth year the survival estimates are 0.802 and 0.783 respectively. The estimated premium cost for a 100 rupees of sum insured is rupees 4.7 for the first year and rupees 26.69 for the fifth year for patients taken cumulatively. Same for CNS1, it is rupees 6.24 and 29.42. Conclusion: Cox-PH model for estimating the survival is recommended since it includes the prognostic factors. The insurance plan suggests to opt for the premium as early as possibly since it costs less and increases later.

Long-Term Survival in Acute Lymphoblastic Leukaemia in Adults Treated according to the LALA 87 Protocol

Chemotherapy ◽  
2003 ◽  
Vol 49 (3) ◽  
pp. 138-145 ◽  
Author(s):  
M. Čolović ◽  
A. Bogdanović ◽  
G. Janković ◽  
N. Kraguljac ◽  
N. Suvajdžić
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Term Survival ◽  
Long Term Survival

Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up

2002 ◽  
Vol 20 (3) ◽  
pp. 694-698 ◽  
Author(s):  
Richard R. Barakat ◽  
Paul Sabbatini ◽  
Dharmendra Bhaskaran ◽  
Margarita Revzin ◽  
Alex Smith ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Residual Disease ◽  
Term Survival ◽  
Long Term Survival ◽  
Cox Proportional Hazard ◽  
Kaplan Meier ◽  
Long Term Follow Up

PURPOSE: To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy. PATIENTS AND METHODS: Records were reviewed of 433 patients who received IP therapy for ovarian cancer between 1984 and 1998; follow-up data were available for 411 patients. IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of platinum-based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. RESULTS: The mean age of patients was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage I, 7; II, 24; III, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. CONCLUSION: Prolonged survival was observed in selected patients receiving IP platinum-based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated.

Cytogenetics of acute lymphoblastic leukaemia in children as a factor in the prediction of long-term survival

1982 ◽  
Vol 52 (3) ◽  
pp. 389-399 ◽  
Author(s):  
L. M. Secker-Walker ◽  
G. J. Swansbury ◽  
R. M. Hardisty ◽  
S. E. Sallan ◽  
O. M. Garson ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Term Survival ◽  
Long Term Survival

Nasal and paranasal sinus mucosal melanoma: Long-term survival outcomes and prognostic factors

2021 ◽  
Vol 42 (6) ◽  
pp. 103070
Author(s):  
Nicholas B. Abt ◽  
Lauren E. Miller ◽  
Tara E. Mokhtari ◽  
Derrick T. Lin ◽  
Jeremy D. Richmon ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Paranasal Sinus ◽  
Mucosal Melanoma ◽  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan

2021 ◽  
Vol 14 (8) ◽  
pp. 705
Author(s):  
Hideki Houzen ◽  
Takahiro Kano ◽  
Kazuhiro Horiuchi ◽  
Masahiro Wakita ◽  
Azusa Nagai ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Rank Test ◽  
Positive Pressure ◽  
Control Group ◽  
Single Center ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier ◽  
Lateral Sclerosis

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan–Meier analysis, which revealed that the median survival durations were 49 (9–88) and 25 (8–41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.

Analysis of Prognostic Factors Influencing Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

2007 ◽  
Vol 32 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Marcella Arru ◽  
Luca Aldrighetti ◽  
Renato Castoldi ◽  
Saverio Di Palo ◽  
Elena Orsenigo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Hepatic Resection ◽  
Metastatic Colorectal Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Factors Influencing
Sign in / Sign up

Export Citation Format

Share Document